United Therapeutics Corp. (UTHR)
487.61
-2.63
(-0.54%)
USD |
NASDAQ |
Sep 04, 16:00
487.66
+0.06
(+0.01%)
Pre-Market: 20:00
United Therapeutics Research and Development Expense (Quarterly) : 146.30M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 146.30M |
| March 31, 2026 | 138.20M |
| December 31, 2025 | 139.50M |
| September 30, 2025 | 127.50M |
| June 30, 2025 | 134.00M |
| March 31, 2025 | 149.00M |
| December 31, 2024 | 133.80M |
| September 30, 2024 | 103.50M |
| June 30, 2024 | 139.60M |
| March 31, 2024 | 104.10M |
| December 31, 2023 | 151.40M |
| September 30, 2023 | 84.70M |
| June 30, 2023 | 89.00M |
| March 31, 2023 | 82.90M |
| December 31, 2022 | 93.90M |
| September 30, 2022 | 66.10M |
| June 30, 2022 | 93.90M |
| March 31, 2022 | 69.00M |
| December 31, 2021 | 82.90M |
| September 30, 2021 | 78.00M |
| June 30, 2021 | 74.30M |
| March 31, 2021 | 174.80M |
| December 31, 2020 | 126.10M |
| September 30, 2020 | 68.70M |
| June 30, 2020 | 89.70M |
| Date | Value |
|---|---|
| March 31, 2020 | 73.20M |
| December 31, 2019 | 113.60M |
| September 30, 2019 | 85.70M |
| June 30, 2019 | 77.10M |
| March 31, 2019 | 97.40M |
| December 31, 2018 | 138.80M |
| September 30, 2018 | 101.10M |
| June 30, 2018 | 82.30M |
| March 31, 2018 | 35.70M |
| December 31, 2017 | 113.60M |
| September 30, 2017 | 55.00M |
| June 30, 2017 | 59.80M |
| March 31, 2017 | 36.20M |
| December 31, 2016 | 66.90M |
| September 30, 2016 | 45.90M |
| June 30, 2016 | 35.20M |
| March 31, 2016 | -0.40M |
| December 31, 2015 | 75.95M |
| September 30, 2015 | 5.403M |
| June 30, 2015 | 49.41M |
| March 31, 2015 | 110.21M |
| December 31, 2014 | 71.48M |
| September 30, 2014 | 118.88M |
| June 30, 2014 | 39.74M |
| March 31, 2014 | 12.45M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Liquidia Corp. | 16.88M |
| MannKind Corp. | 18.00M |
| Vertex Pharmaceuticals, Inc. | 993.80M |
| Alnylam Pharmaceuticals, Inc. | 413.13M |
| Savara, Inc. | 21.95M |